| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) provided by financing activities | 6,265,852 | 404,369 |
| Net decrease in cash and cash equivalents | 2,375,152 | -1,639,642 |
| Cash and cash equivalents at beginning of period | 2,434,528 | - |
| Cash and cash equivalents at end of period | 4,809,680 | - |
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX)